GLPG2222 150 mg q.d. ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
299	嚢胞性線維症	1

299. 嚢胞性線維症

---

臨床試験数 : 1,696 /  薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03045523 (ClinicalTrials.gov)	January 2017	26/1/2017	A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis	A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis Harbouring One F508del CFTR Mutation and a Second Gating (Class III) Mutation	Cystic Fibrosis	Drug: GLPG2222 150 mg q.d.;Drug: GLPG2222 300 mg q.d.;Drug: Placebo	Galapagos NV	NULL	Completed	18 Years	99 Years	All	37	Phase 2	Australia;Belgium;Czechia;Germany;Ireland;United Kingdom